KPI-121 0.25% Approval Status
FDA Approved: No
Brand name: KPI-121 0.25%
Generic name: loteprednol etabonate
Company: Kala Pharmaceuticals, Inc.
Treatment for: Dry Eye Disease
KPI-121 0.25% (loteprednol etabonate) is an ophthalmic corticosteroid formulation in development for the temporary relief of signs and symptoms of dry eye disease.
Development Status and FDA Approval Process for KPI-121 0.25%
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.